Ocular Insulin Delivery Enhanced by Prostaglandin Analogues Patent Application
Summary
The USPTO has published a patent application (US20260083822A1) for a novel ocular insulin delivery system. The invention utilizes prostaglandin analogues to enhance insulin permeability across ocular tissues, offering a non-invasive alternative to injections for therapeutic effects.
What changed
The United States Patent and Trademark Office (USPTO) has published a patent application, US20260083822A1, detailing a pharmaceutical composition for topical ocular insulin delivery. The core innovation is the use of prostaglandin analogues as penetration enhancers to improve insulin absorption through the eye. This formulation aims to provide a non-invasive method for administering insulin, potentially for systemic or local therapeutic effects, without the need for injections.
This patent application signifies a potential new development in drug delivery for diabetes management. While not a final rule or enforcement action, it indicates a novel approach that pharmaceutical and medical device companies involved in ophthalmic drug delivery and diabetes treatment may wish to monitor. The application was filed on November 28, 2025, and published with a projected application date of March 26, 2026.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Topical Ocular Insulin Delivery Enhanced by Prostaglandin Analogues
Application US20260083822A1 Kind: A1 Mar 26, 2026
Inventors
David Harold Gosiengfiao
Abstract
A pharmaceutical composition is disclosed comprising an insulin, a set of excipients, and a penetration enhancer, wherein the penetration enhancer is a prostaglandin analogue configured to enhance the permeability of insulin upon topical ocular administration. The composition enables increased transport of insulin across ocular tissues, improving absorption and bioavailability following topical delivery to the eye. The formulation includes pharmaceutically acceptable excipients such as surfactants, buffering agents, viscosity enhancers, tonicity agents, preservatives, and solvents suitable for ophthalmic use. The invention provides a non-invasive route of administering insulin through the eye, allowing systemic or local therapeutic effects without injection.
CPC Classifications
A61K 38/28 A61K 9/0048 A61K 31/5575 A61P 3/08
Filing Date
2025-11-28
Application No.
19403706
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.